Scientists have discovered that Parkinson’s disease isn’t solely a neurological disorder impacting movement, but also triggers a fundamental shift in how the body generates energy at the cellular level. The finding, while preliminary, suggests a broader metabolic component to the disease than previously understood and could open new avenues for treatment.
Parkinson’s disease, affecting an estimated 60 years or older, is characterized by the progressive loss of muscle control, leading to tremors, stiffness and impaired balance. The disease is the second most common neurodegenerative disorder and the most common movement disorder. The core of the problem lies in the deterioration of nerve cells in the brain, specifically those producing dopamine, a chemical messenger crucial for smooth, purposeful movement. Research indicates that by the time symptoms appear, individuals with Parkinson’s often have lost 60 to 80% of these dopamine-producing cells in a region called the substantia nigra.
But, the new research highlights a concurrent decline in the function of norepinephrine-producing nerve endings. Norepinephrine is a key neurotransmitter controlling automatic bodily functions like pulse and blood pressure. This loss may explain non-movement related symptoms such as fatigue and blood pressure fluctuations, broadening the clinical picture of the disease.
A hallmark of the affected brain cells in Parkinson’s patients is the presence of Lewy bodies – abnormal deposits of the protein alpha-synuclein. While the exact role of these Lewy bodies remains unclear, some research suggests a failure in the cell’s protein disposal system may contribute to their formation. This failure leads to a buildup of proteins to harmful levels, potentially triggering cell death. Evidence also points to clumps of protein inside brain cells contributing to neuronal demise.
The disease manifests differently in individuals. While adult-onset Parkinson’s is the most prevalent form, early-onset (between 21-40 years) and juvenile-onset (before age 21) cases also occur. The progression of the disease and the degree of impairment vary significantly from person to person, with some individuals maintaining productive lives while others experience rapid disability. Complications, such as falls and pneumonia, can arise as the disease advances.
Despite these complications, studies suggest that life expectancy for people with Parkinson’s is comparable to the general population, a trend likely influenced by increasing overall life expectancy. The number of individuals diagnosed with Parkinson’s is expected to rise in the future as populations age.
Currently, there is no known prevention for Parkinson’s disease. Treatment focuses on managing symptoms and improving quality of life. Further research is underway to understand the underlying causes of the disease and develop more effective therapies.
